文献速递胸部肿瘤

中央型非小细胞肺癌五分割立体定向体部放疗方案的安全性与疗效:NRG Oncology/RTOG 0813 试验

Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial.
PubMed 文献 · J Clin Oncol · 2019-04-03

NRG Oncology/RTOG 0813 是一项 I/II 期研究,纳入 120 例医学上不可手术、活检证实的 T1-2(≤5 cm)N0M0 中央型非小细胞肺癌患者,接受 10 至 12 Gy/次、共 5 次的立体定向体部放疗。最大耐受剂量为 12.0 Gy/次,剂量限制性毒性概率为 7.2%(95% CI,2.8% 至 14.5%),11.5 和 12.0 Gy/次队列的 2 年局部控制率分别为 89.4% 和 87.9%,总生存率分别为 67.9% 和 72.7%。

要点

  • 中央型早期非小细胞肺癌五分割立体定向体部放疗的最大耐受剂量为 12.0 Gy/次。
  • 最大耐受剂量下剂量限制性毒性概率为 7.2%(95% CI,2.8% 至 14.5%)。
  • 11.5 和 12.0 Gy/次队列 2 年局部控制率分别为 89.4% 和 87.9%。

核心结论

  • 本研究最大耐受剂量为 12.0 Gy/次,与 7.2% 的剂量限制性毒性相关,并伴有高肿瘤控制率。
  • 在主要为老年合并症患者的医学上不可手术组中,结局与外周早期肿瘤患者相当。

研究设计与样本

  • NRG Oncology/RTOG 0813 是一项 I/II 期研究,旨在确定中央型非小细胞肺癌立体定向体部放疗的最大耐受剂量、疗效和毒性。
  • 2009 年 2 月至 2013 年 9 月共纳入 120 例医学上不可手术、活检证实的 T1 至 2(≤5 cm)N0M0 中央型非小细胞肺癌患者。
  • 采用剂量递增的五分割立体定向体部放疗方案,范围为 10 至 12 Gy/次,在 1.5 至 2 周内完成。
  • 剂量限制性毒性定义为第一年内发生的任何治疗相关 3 级或更严重的预设毒性。
  • 最大耐受剂量定义为剂量限制性毒性概率最接近但不超过 20% 的立体定向体部放疗剂量。

主要发现

  • 患者为老年人,女性略多,多数体力状态评分为 0 至 1。
  • 大多数癌症为 T1(65%)和鳞状细胞癌(45%);最接近计划靶区/风险最高的器官是主支气管和大血管。
  • 中位随访时间为 37.9 个月;5 例患者发生剂量限制性毒性。
  • 在 11.5 和 12.0 Gy/次队列的 71 例可评估患者中,2 年局部控制率分别为 89.4%(90% CI,81.6% 至 97.4%)和 87.9%(90% CI,78.8% 至 97.0%)。
  • 上述 71 例可评估患者的 2 年总生存率分别为 67.9%(95% CI,50.4% 至 80.3%)和 72.7%(95% CI,54.1% 至 84.8%),无进展生存率分别为 52.2%(95% CI,35.3% 至 66.6%)和 54.5%(95% CI,36.3% 至 69.6%)。

关键数值与推荐

  • 最大耐受剂量为 12.0 Gy/次,该剂量下剂量限制性毒性概率为 7.2%(95% CI,2.8% 至 14.5%)。
  • 剂量递增范围为 10 至 12 Gy/次,共 5 次,在 1.5 至 2 周内完成。
  • 剂量限制性毒性定义为第一年内发生的任何治疗相关 3 级或更严重的预设毒性。
  • 最大耐受剂量定义为剂量限制性毒性概率最接近但不超过 20% 的立体定向体部放疗剂量。

临床怎么用

  • 原文未据此给出推荐。
  • 研究结论为:最大耐受剂量为 12.0 Gy/次,与 7.2% 的剂量限制性毒性及高肿瘤控制率相关。
  • 在主要为老年合并症患者的医学上不可手术组中,结局与外周早期肿瘤患者相当。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Patients with centrally located early-stage non-small-cell lung cancer (NSCLC) are at a higher risk of toxicity from high-dose ablative radiotherapy. NRG Oncology/RTOG 0813 was a phase I/II study designed to determine the maximum tolerated dose (MTD), efficacy, and toxicity of stereotactic body radiotherapy (SBRT) for centrally located NSCLC. MATERIALS AND METHODS: Medically inoperable patients with biopsy-proven, positron emission tomography-staged T1 to 2 (≤ 5 cm) N0M0 centrally located NSCLC were accrued into a dose-escalating, five-fraction SBRT schedule that ranged from 10 to 12 Gy/fraction (fx) delivered over 1.5 to 2 weeks. Dose-limiting toxicity (DLT) was defined as any treatment-related grade 3 or worse predefined toxicity that occurred within the first year. MTD was defined as the SBRT dose at which the probability of DLT was closest to 20% without exceeding it. RESULTS: One hundred twenty patients were accrued between February 2009 and September 2013. Patients were elderly, there were slightly more females, and the majority had a performance status of 0 to 1. Most cancers were T1 (65%) and squamous cell (45%). Organs closest to planning target volume/most at risk were the main bronchus and large vessels. Median follow-up was 37.9 months. Five patients experienced DLTs; MTD was 12.0 Gy/fx, which had a probability of a DLT of 7.2% (95% CI, 2.8% to 14.5%). Two-year rates for the 71 evaluable patients in the 11.5 and 12.0 Gy/fx cohorts were local control, 89.4% (90% CI, 81.6% to 97.4%) and 87.9% (90% CI, 78.8% to 97.0%); overall survival, 67.9% (95% CI, 50.4% to 80.3%) and 72.7% (95% CI, 54.1% to 84.8%); and progression-free survival, 52.2% (95% CI, 35.3% to 66.6%) and 54.5% (95% CI, 36.3% to 69.6%), respectively. CONCLUSION: The MTD for this study was 12.0 Gy/fx; it was associated with 7.2% DLTs and high rates of tumor control. Outcomes in this medically inoperable group of mostly elderly patients with comorbidities were comparable with that of patients with peripheral early-stage tumors.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Bezjak A, Paulus R, Gaspar LE, et al. Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial. J Clin Oncol. 2019. PMID: 30943123. doi:10.1200/JCO.18.00622

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。